Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
University of California, Irvine
Neonc Technologies, Inc.
ViroMissile, Inc.
Jazz Pharmaceuticals
Seagen Inc.
Arvinas Inc.
Tizona Therapeutics, Inc
Aulos Bioscience, Inc.
Genentech, Inc.
Brigham and Women's Hospital
Baylor College of Medicine
MacroGenics
Alliance for Clinical Trials in Oncology
Daiichi Sankyo
One-carbon Therapeutics AB
University of Nebraska
Zhejiang University
Adela, Inc
Perspective Therapeutics
Innate Pharma
Var2 Pharmaceuticals
GlaxoSmithKline
Tanabe Pharma America, Inc.
AbbVie
LigaChem Biosciences, Inc.
Washington University School of Medicine
Travera Inc
Nurix Therapeutics, Inc.
Jonsson Comprehensive Cancer Center
Marengo Therapeutics, Inc.
Apollomics Inc.
University of California, Irvine
ModeX Therapeutics, An OPKO Health Company
Cancer Research UK
Columbia University
Merus B.V.
Pack Health
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Taiho Pharmaceutical Co., Ltd.
European Organisation for Research and Treatment of Cancer - EORTC
Cancer Research UK
Zhujiang Hospital
Second Affiliated Hospital of Guangzhou Medical University
Beijing Friendship Hospital
Hospices Civils de Lyon